172 related articles for article (PubMed ID: 14672496)
1. ACOG Committee Opinion. Use of progesterone to reduce preterm birth.
American College of Obstetricians and Gynecologists
Obstet Gynecol; 2003 Nov; 102(5 Pt 1):1115-6. PubMed ID: 14672496
[TBL] [Abstract][Full Text] [Related]
2. Use of progesterone to reduce preterm birth.
American College of Obstetrics and Gynecologist Committee Opinion
Int J Gynaecol Obstet; 2004 Jan; 84(1):93-4. PubMed ID: 14959752
[TBL] [Abstract][Full Text] [Related]
3. The rebirth of progesterone in the prevention of preterm labor.
Schmouder VM; Prescott GM; Franco A; Fan-Havard P
Ann Pharmacother; 2013 Apr; 47(4):527-36. PubMed ID: 23535817
[TBL] [Abstract][Full Text] [Related]
4. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
5. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
6. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
Meis PJ; Klebanoff M; Thom E; Dombrowski MP; Sibai B; Moawad AH; Spong CY; Hauth JC; Miodovnik M; Varner MW; Leveno KJ; Caritis SN; Iams JD; Wapner RJ; Conway D; O'Sullivan MJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
N Engl J Med; 2003 Jun; 348(24):2379-85. PubMed ID: 12802023
[TBL] [Abstract][Full Text] [Related]
7. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
[TBL] [Abstract][Full Text] [Related]
8. 17-α hydroxyprogesterone caproate for the prevention of preterm birth.
Gupta S; Roman AS
Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770
[TBL] [Abstract][Full Text] [Related]
9. Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
Stetson B; Hibbard JU; Wilkins I; Leftwich H
Obstet Gynecol; 2016 Nov; 128(5):983-988. PubMed ID: 27741201
[TBL] [Abstract][Full Text] [Related]
10. Recurrent hope for the treatment of preterm delivery.
Doggrell SA
Expert Opin Pharmacother; 2003 Dec; 4(12):2363-6. PubMed ID: 14640934
[TBL] [Abstract][Full Text] [Related]
11. Does progesterone treatment influence risk factors for recurrent preterm delivery?
Meis PJ; Klebanoff M; Dombrowski MP; Sibai BM; Leindecker S; Moawad AH; Northen A; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S
Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
[TBL] [Abstract][Full Text] [Related]
12. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
[TBL] [Abstract][Full Text] [Related]
13. Iatrogenic autoimmune progesterone dermatitis caused by 17alpha-hydroxyprogesterone caproate for preterm labor prevention.
Bandino JP; Thoppil J; Kennedy JS; Hivnor CM
Cutis; 2011 Nov; 88(5):241-3. PubMed ID: 22272488
[TBL] [Abstract][Full Text] [Related]
14. 17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographically short cervix: A randomized controlled trial.
Pirjani R; Heidari R; Rahimi-Foroushani A; Bayesh S; Esmailzadeh A
J Obstet Gynaecol Res; 2017 Jan; 43(1):57-64. PubMed ID: 27775195
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
Facchinetti F; Vaccaro V
Minerva Ginecol; 2009 Oct; 61(5):401-9. PubMed ID: 19749671
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
Saghafi N; Khadem N; Mohajeri T; Shakeri MT
J Obstet Gynaecol Res; 2011 Oct; 37(10):1342-5. PubMed ID: 21564406
[TBL] [Abstract][Full Text] [Related]
17. 17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
Hines M; Lyseng-Williamson KA; Deeks ED
Clin Drug Investig; 2013 Mar; 33(3):223-7. PubMed ID: 23413110
[TBL] [Abstract][Full Text] [Related]
18. Treatment options and recommendations to reduce preterm births in women with short cervix.
Slager J; Lynne S
J Midwifery Womens Health; 2012 Jul; 57 Suppl 1():S12-8. PubMed ID: 22776244
[TBL] [Abstract][Full Text] [Related]
19. Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
Feghali M; Venkataramanan R; Caritis S
Semin Perinatol; 2014 Dec; 38(8):516-22. PubMed ID: 25256193
[TBL] [Abstract][Full Text] [Related]
20. Salivary progesterone and estriol among pregnant women treated with 17-alpha-hydroxyprogesterone caproate or placebo.
Klebanoff MA; Meis PJ; Dombrowski MP; Zhao Y; Moawad AH; Northen A; Sibai BM; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Leveno KJ; Miodovnik M; Conway D; Wapner RJ; Carpenter M; Mercer BM; Ramin SM; Thorp JM; Peaceman AM;
Am J Obstet Gynecol; 2008 Nov; 199(5):506.e1-7. PubMed ID: 18456237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
